Cargando…

Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)

The authors of this “Letter to the Editors” express their major concern about selective and biased reporting in this paper.

Detalles Bibliográficos
Autores principales:	Boehle, Andreas, Kahmann, Frank, Henkel, Thomas Oliver, Zimmermann, Joerg, Machtens, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954738/ https://www.ncbi.nlm.nih.gov/pubmed/33507360 http://dx.doi.org/10.1007/s00432-020-03499-x

Ejemplares similares

Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
por: Wiegel, Thomas, et al.
Publicado: (2020)

Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
por: Wiegel, Thomas, et al.
Publicado: (2021)

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
por: Boehle, Andreas, et al.
Publicado: (2022)

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
por: Albers, Peter, et al.
Publicado: (2020)

Patient preferences for treatment modalities for localised prostate cancer
por: Teunissen, Frederik R., et al.
Publicado: (2022)

Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer
por: Alyamani, Najlaa, et al.
Publicado: (2021)

Letter to the Editor Re: Orthopaedic Surgeons Prefer to Participate in Expertise-based Randomized Trials: Bednarska E, Bryant D, Devereaux, PJ. Orthopaedic Surgeons Prefer to Participate in Expertise-based Randomized trials. Clin Orthop Relat Res. 2008;466:1734–1744
por: Biau, David J., et al.
Publicado: (2008)

Re: Prognosis of prostate cancer and prostate - specific antigen levels
por: Joob, Beuy, et al.
Publicado: (2019)

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
por: Nicholls, Luke, et al.
Publicado: (2020)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Participant Preferences for the Provision of Registration Trials Results
por: Tajima, Soichiro, et al.
Publicado: (2013)

Re-epithelialization of the prostatic urethra after two-micron laser resection of the prostate
por: Luo, Guang-Heng, et al.
Publicado: (2016)

Re: Geriatric 8 screening of frailty in patients with prostate cancer
por: Sugimura, Rumiko, et al.
Publicado: (2020)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO)
por: Pasquier, David, et al.
Publicado: (2017)

Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
por: Gómez Rivas, Juan, et al.
Publicado: (2022)

Participants’ perspectives and preferences on clinical trial result dissemination: The TRUST Thyroid Trial experience
por: Racine, Emmy, et al.
Publicado: (2019)

Preference Elicitation and Treatment Decision-Making Among Men Diagnosed With Prostate Cancer: Randomized Controlled Trial Results of Healium
por: Diefenbach, Michael A, et al.
Publicado: (2023)

Re-examining the Meis Trial for Evidence of False-Positive Results
por: Sibai, Baha, et al.
Publicado: (2020)

Re: Accelerating clinical trial implementation in the context of the COVID-19 pandemic by Diallo et al
por: Rys, Andrzej, et al.
Publicado: (2022)

Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial
por: Barry Delongchamps, Nicolas, et al.
Publicado: (2021)

Hand preference for the visual and auditory modalities in humans
por: Yang, Yuqian, et al.
Publicado: (2021)

The Interaction Between Text Modality and the Learner’s Modality Preference Influences Comprehension and Cognitive Load
por: Lehmann, Janina, et al.
Publicado: (2020)

RE: Diffusion-Weighted Imaging of Prostate Cancer: How Can We Use It Accurately?
por: Akgun, Veysel, et al.
Publicado: (2013)

Re: Preliminary assessment of neck circumference in benign prostatic hyperplasia in patients with metabolic syndrome
por: Besiroglu, Huseyin, et al.
Publicado: (2017)

Re: Commentary on “The association between sexual function and prostate cancer risk in US veterans”
por: Vidal, Adriana C, et al.
Publicado: (2018)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Re: Protective effects of Chromolaena odorata extract on experimental benign prostatic hyperplasia in rats
por: Alexandra Oliveira, Paula, et al.
Publicado: (2023)

Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials
por: Henderson, Randal H., et al.
Publicado: (2013)

Reply to Letter to Editor: Orthopaedic Surgeons Prefer to Participate in Expertise-based Randomized Trials
por: Bryant, Dianne, et al.
Publicado: (2008)

Patient preferences for outcomes in critical care trials (OPTICS): preliminary results
por: Muscedere, J, et al.
Publicado: (2015)

Returning aggregate results of clinical trials: Empirical data of patient preferences
por: Aldinger, Carmen E., et al.
Publicado: (2019)

Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36
por: Shore, Neal D.
Publicado: (2022)

Re: “Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy” by Wilson and Flotte
por: Shieh, Perry B., et al.
Publicado: (2020)

Preferences of biobank participants for receiving actionable genomic test results: results of a re-contacting study
por: Henrikson, Nora B., et al.
Publicado: (2021)

Re-evaluating randomized clinical trials of psychological interventions: Impact of response shift on the interpretation of trial results
por: Verdam, M. G. E., et al.
Publicado: (2021)

Implementation and scientific evaluation of rehabilitative sports groups for prostate cancer patients: study protocol of the ProRehab Study
por: Zopf, Eva M, et al.
Publicado: (2012)

Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
por: Cox, R A, et al.
Publicado: (2008)

Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'
por: Shah, S I A, et al.
Publicado: (2013)

Modalities for Imaging of Prostate Cancer
por: Hou, A. H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_h0gujt3lmo8tqm3dkb2td41rr9